Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
Open Access
- 23 June 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy - Oncolytics
- Vol. 18, 272-281
- https://doi.org/10.1016/j.omto.2020.06.016
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2017YFA0104500)
- National Natural Science Foundation of China (81670166, 81530046, 81870140)
- Innovative Research Groups of the National Natural Science Foundation of China (81621001)
- Beijing Municipal Science & Technology Commission (Z171100001017098)
- Project of Health Collaborative Innovation (201704020214)
- Peking University Clinical Scientist Program (BMU2019LCKXJ003)
- Scientific Research Foundation for Capital Medicine Development (2018-2-4084)
This publication has 36 references indexed in Scilit:
- Eradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoproteinBlood, 2015
- The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive forIn VivoAntitumor ActivityCancer Immunology Research, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaThe New England Journal of Medicine, 2014
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28–OX40 “Super-stimulation”Molecular Therapy, 2013
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptorsNature Reviews Clinical Oncology, 2013
- Molecular mechanisms of T cell co-stimulation and co-inhibitionNature Reviews Immunology, 2013
- Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaBlood, 2013
- Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory DomainsHuman Gene Therapy, 2007